Patents by Inventor Steven C. Hodges
Steven C. Hodges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6391543Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS118 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS118-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS118 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: GrantFiled: April 23, 1998Date of Patent: May 21, 2002Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe
-
Publication number: 20020045164Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as LS170 and transcribed from lung tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung, such as lung cancer. Also provided are antibodies which specifically bind to a LS170-encoded polypeptide or protein, and agonists or inhibitors which prevent action of tissue-specific LS170 polypeptides, which molecules are useful for the therapeutic treatment of lung diseases, tumors or metastases.Type: ApplicationFiled: June 11, 1998Publication date: April 18, 2002Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Publication number: 20020045165Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS135 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer.Type: ApplicationFiled: December 16, 1998Publication date: April 18, 2002Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, MICHAEL R. KLASS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, JON D. KRATOCHVIL, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Publication number: 20020037503Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS274 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer.Type: ApplicationFiled: November 17, 1998Publication date: March 28, 2002Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Publication number: 20020034749Abstract: A set of contiguous and partially overlapping CDNA sequences and polypeptides encoded thereby, designated as BS265 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer.Type: ApplicationFiled: May 7, 2001Publication date: March 21, 2002Inventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa A. Roberts-Rapp, John C. Russell, Stephen D. Stroupe
-
Publication number: 20020034740Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS325 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer.Type: ApplicationFiled: January 21, 1999Publication date: March 21, 2002Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Publication number: 20020018990Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS124 and transcribed from breast tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to a BS124-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS124 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.Type: ApplicationFiled: June 19, 1998Publication date: February 14, 2002Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, JOHN C. RUSSELL, CHRISTI P. SCHEFFEL, STEPHEN D. STROUPE, HONG YU
-
Publication number: 20010055758Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS118 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS118-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS118 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: ApplicationFiled: April 23, 1998Publication date: December 27, 2001Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COPLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Publication number: 20010010904Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS 198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS 198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS 198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.Type: ApplicationFiled: March 30, 1998Publication date: August 2, 2001Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, MARK HAYDEN, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
-
Patent number: 6252047Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS108 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS108-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS108 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: GrantFiled: March 15, 2000Date of Patent: June 26, 2001Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
-
Patent number: 6207380Abstract: Polypeptides and polynucleotides useful for detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary cancer, are described. These sequences are derived from keratin/cytokeratin, CAS, or mat-8 polypeptides and polynucleotides. Also provided are antibodies which specifically bind to keratin/cytokeratin, CAS, or mat-8-encoded polypeptides or proteins, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.Type: GrantFiled: September 15, 1998Date of Patent: March 27, 2001Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Eric Russell, Stephen D. Stroupe
-
Patent number: 6183952Abstract: A novel member of the uteroglobin family of proteins, designated as BU101, is described. BU101 is defined by a set of contiguous and partially overlapping RNA sequences transcribed from breast tissue, and polypeptides encoded thereby. A fully sequenced clone representing the longest continuous sequence of BU101 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BU101-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BU101 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.Type: GrantFiled: August 15, 1997Date of Patent: February 6, 2001Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe
-
Patent number: 6130043Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS108 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS108-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS108 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: GrantFiled: May 1, 1998Date of Patent: October 10, 2000Assignee: Abbott LaboratoriesInventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
-
Patent number: 6110675Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS112 and transcribed from prostate tissue is described. A fully sequenced clone representing a continuous sequence of PS112 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS112-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS112 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: GrantFiled: October 8, 1997Date of Patent: August 29, 2000Assignee: Abbott LaboratoriesInventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
-
Patent number: 5939265Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.Type: GrantFiled: November 5, 1997Date of Patent: August 17, 1999Assignee: Abbott LaboratoriesInventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Steven D. Stroupe
-
Patent number: 5702953Abstract: A device for particle agglutination analysis and a method for its use. The device includes means forming a longitudinally extending channel, an opening communicating from the exterior of the device to a first end of the channel, a reservoir communicating with the second end of the channel, and a vent opening communicating from the reservoir to the exterior of the apparatus. The channel has a sufficiently large cross section and the vent is positioned such that, when the channel is in a vertical position, a given amount of fluid, introduced through the opening into the channel will flow by gravity through the channel and into the reservoir, filling the channel to a desired height and the reservoir to the same height without flowing through the vent, while air escapes through the vent. Gravity causes sufficient movement of the particles so that agglutination may occur.Type: GrantFiled: June 4, 1992Date of Patent: December 30, 1997Assignee: Abbott LaboratoriesInventors: Carol Mazurek, Charles L. Nelson, Steven C. Hodges, James W. Scheffel